Skip to content
Biodatica
Start free

West German Study Group

Anderlecht, Baden-Wurttemberg

OncologyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

5w agoTrial registeredJun 8, 2026Source filing (opens the source filing in a new tab)

Momentum

83no change

Momentum 83 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

321 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jun 30, 2026

    Breast Cancer, Triple-negative Breast Cancer · NOT_YET_RECRUITING · sponsor: West German Study Group · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

    ClinicalTrials.gov · NCT07178730 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Nov 27, 2025

    Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer · RECRUITING · sponsor: West German Study Group · Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

    ClinicalTrials.gov · NCT07281833 (opens the source filing in a new tab)

  3. Trial

    NA registered

    Aug 15, 2021

    Hypersensitivity, Food · COMPLETED · sponsor: University of Zurich · Prospective Study About Sensitization Pattern to Insects as Food Source in Patients With House Dust Mite Allergy

    ClinicalTrials.gov · NCT04239131 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jun 1, 2013

    Breast Cancer · COMPLETED · sponsor: West German Study Group · Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

    ClinicalTrials.gov · NCT01815242 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources